Skip to main content
. 2022 Jul;18(7 Suppl 2):6.

Figure 5.

Figure 5.

Rates of clinical remission at 12 weeks among patients with moderately to severely active ulcerative colitis treated with deucravacitinib or placebo in the phase 2 LATTICE-UC study. aThe numbers of patients were based on the electronic case report form. BID, twice daily. Adapted from Danese S et al. DDW abstract 965. Gastroenterology. 2022;162(suppl 1).4